Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
indiana blog main
indiana top stories
life sciences
national blog main
new york blog main
6
×
new york top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
national top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
fda
national
fremanezumab
teva pharmaceutical
amgen
bristol-myers squibb
calcitonin gene-related peptide
drug prices
eptinezumab
erenumab
galcanezumab
immunotherapy
What
approval
6
×
drug
fda
new
won
bio
class
companies
developed
migraine
oral
roundup
therapy
treat
advanced
agency
aimmune
allergy
alnylam’s
amgen
approved
arguments
awarded
bff
bid
big
biogen’s
biopharmaceutical
boehringer
candidates
commercialized
competitors
conference
convo
deals
decades
devoted
diabetes
disease
drugs
Language
unset
Current search:
approval
×
" new york blog main "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines